Understanding the Transition from Normal Melanocytes to Nevus to Melanoma (NevustoMel)
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Genetic
Study Type: Observational
SUMMARY
The primary objective of this study is to identify the molecular identity profiles of all cellular states that characterize the progression from benign nevi to malignant melanoma in CAYA patients with L/GCMN. The secondary objectives are: * To longitudinally characterize the cell-free DNA (cfDNA) from CAYA patients. * To improve the early diagnosis and treatments for intermediate conditions such as L/GCMN through evidence-based interpretation of personal risk from endogenous or exogenous sources. * To test pre-clinical strategies to best model and improve patient response.
Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:
• Congenital nevus with estimated size of 20 cm
• Be over 18 years of age
Locations
Other Locations
France
French National Institute of Health and Medical Research
RECRUITING
Marseille
Spain
Hospital Clínic de Barcelona (Dermatology service)
RECRUITING
Barcelona
Contact Information
Primary
Susana Puig Sardà, MD, PhD
spuig@clinic.cat
+34932275400
Backup
Adrián López Canosa, PhD
lopez64@recerca.clinic.cat
Time Frame
Start Date: 2024-01-01
Estimated Completion Date: 2026-11-30
Participants
Target number of participants: 100
Treatments
L/GCMN
Patients with congenital nevus with estimated size of 20 cm or more in adulthood (\> 18 years old)
Melanoma
Patients affected with Spitz-type or conventional melanomas in patients under 30 years of age
Related Therapeutic Areas
Sponsors
Collaborators: Institut Curie, University Hospital Tuebingen, Institut National de la Santé Et de la Recherche Médicale, France, Karolinska Institutet, Medical University of Gdansk, Maria Sklodowska-Curie National Research Institute of Oncology, German Cancer Research Center, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Princess Maxima Center for Pediatric Oncology, University Of Perugia, Institut Català d'Oncologia, University of Florence
Leads: Fundacion Clinic per a la Recerca Biomédica